Saturday 21 May 2022
- Advertisement -

Strategic alliance to deal with metabolic disorder

Join Sirf News on

and/or

Bengaluru: Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area. The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity.

The collaboration is for the purpose of discovery and  of small molecule inhibitors through to the first phase proof of mechanism in metabolic disorders therapeutic area.

As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru, India) and Jubilant Chemsys (Noida, India).

Dr Sriram Rajagopal, Chief Scientific Officer, Jubilant Biosys, said about the alliance, “We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This demonstrates Jubilant’s commitment to global innovation and we look forward to a long mutually beneficial partnership.”

Dr Philip Just Larsen, Vice President, Global Head of Diabetes Research & Translational Medicine, Sanofi Deutschland GmbH, said, “The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes.”

About Jubilant Biosys Ltd

Jubilant Biosys is a Bengaluru, India based subsidiary of Jubilant Life Sciences Ltd., an integrated global and life sciences Company headquartered in Noida, India. Jubilant Biosys provides integrated discovery solutions to the global industry. The Company has pioneered the risk shared collaborative discovery research model and demonstrated capabilities over the years through multiple partnerships with global pharmaceuticals firms in the therapeutic areas of oncology, metabolic disorders, pain & inflammation, CNS and others.

For more information, visit this site. For business development, write to Dr Rajiv Tyagi.

PR Newswire

 

Join Sirf News on

and/or

Similar Articles

Comments

Contribute to our cause

Sirf News needs to recruit journalists in large numbers to increase the volume of its reports and articles to at least 100 a day, which will make us mainstream, which is necessary to challenge the anti-India discourse by established media houses. Besides there are monthly liabilities like the subscription fees of news agencies, the cost of a dedicated server, office maintenance, marketing expenses, etc. Donation is our only source of income. Please serve the cause of the nation by donating generously.

Or scan to donate

Swadharma QR Code
Advertisment
Sirf News Facebook Page QR Code
Facebook page of Sirf News: Scan to like and follow

Most Popular

[prisna-google-website-translator]
%d bloggers like this: